S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NASDAQ:AVTX

Avalo Therapeutics (AVTX) Stock Price, News & Analysis

$4.75
+0.13 (+2.81%)
(As of 03/27/2024 ET)
Today's Range
$4.60
$4.86
50-Day Range
$4.10
$5.80
52-Week Range
$3.95
$1,130.40
Volume
2.94 million shs
Average Volume
31,679 shs
Market Capitalization
$427,500.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Avalo Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
74.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.21mentions of Avalo Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($95.24) to ($16.67) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.36 out of 5 stars

AVTX stock logo

About Avalo Therapeutics Stock (NASDAQ:AVTX)

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

AVTX Stock Price History

AVTX Stock News Headlines

Why Is Avalo Therapeutics (AVTX) Stock Up 326% Today?
my top trade on these 9 tickers
This indicator is uniquely designed to spot the most significant moves in the top stocks out there (and according to our backtesting it has historically nailed these moves with a stunning 90% accuracy). Now, most folks have been saying NVDA is way overbought or overpriced. They didn’t want to “buy at the top” 6 weeks ago… Or again 4 weeks ago… or again 2 weeks ago… And it’s not their fault! That’s what all the talking heads were saying too. But the Apex Indicator would have clearly shown that these were opportunities to buy. And, sure enough, Nvidia slammed through the recommended targets again and again.
Avalo Therapeutics (NASDAQ:AVTX) Trading Down 2.9%
Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
CBOE shift unlocks new weekend income strategy
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend.
Avalo Therapeutics Inc AVTX
Avalo Completes Divestiture of AVTX-800 Series
Why Avalo Therapeutics Stock Is Up Today
Crude Oil Rises 2%; Avalo Therapeutics Shares Spike Higher
See More Headlines
Receive AVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/02/2022
Today
3/28/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AVTX
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Net Income
$-41,660,000.00
Net Margins
-1,475.02%
Pretax Margin
-1,473.60%

Debt

Sales & Book Value

Annual Sales
$18.05 million
Book Value
($275.57) per share

Miscellaneous

Free Float
85,000
Market Cap
$427,500.00
Optionable
Not Optionable
Beta
0.69
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Garry A. Neil M.D. (Age 70)
    Chairman of the Board, President & CEO
    Comp: $601.9k
  • Mr. Christopher Ryan SullivanMr. Christopher Ryan Sullivan (Age 40)
    CFO & Head of Investor relations
    Comp: $466.94k
  • Dr. Solomon H. Snyder M.D. (Age 85)
    Founder and Chairman of Scientific Advisory Board
  • Dr. Barbara S. Slusher Ph.D. (Age 59)
    Founder and Member of Scientific Advisory Board
  • Dr. Lisa Hegg Ph.D.
    Senior Vice President of Program Management, Corporate Infrastructure & Clinical Operations
  • Ms. Colleen Matkowski
    Senior Vice President of Global Regulatory Affairs & Quality Assurance
  • Dr. Dino C. Miano Ph.D.
    Senior Vice President of CMC & Technical Operations

AVTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Avalo Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avalo Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AVTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVTX, but not buy additional shares or sell existing shares.
View AVTX analyst ratings
or view top-rated stocks.

How have AVTX shares performed in 2024?

Avalo Therapeutics' stock was trading at $9.10 at the beginning of 2024. Since then, AVTX shares have decreased by 47.8% and is now trading at $4.75.
View the best growth stocks for 2024 here
.

Are investors shorting Avalo Therapeutics?

Avalo Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 67,200 shares, an increase of 10.3% from the February 29th total of 60,900 shares. Based on an average daily volume of 51,300 shares, the days-to-cover ratio is currently 1.3 days.
View Avalo Therapeutics' Short Interest
.

When is Avalo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our AVTX earnings forecast
.

How were Avalo Therapeutics' earnings last quarter?

Avalo Therapeutics, Inc. (NASDAQ:AVTX) released its earnings results on Wednesday, March, 2nd. The company reported ($460.80) earnings per share for the quarter, missing analysts' consensus estimates of ($432.00) by $28.80.

When did Avalo Therapeutics' stock split?

Shares of Avalo Therapeutics reverse split before market open on Friday, December 29th 2023. The 1-240 reverse split was announced on Friday, December 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

Who are Avalo Therapeutics' major shareholders?

Avalo Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Armistice Capital, Llc, Caissa Capital Management Ltd, Christopher Ryan Sullivan, Garry Arthur Neil, H Jeffrey Wilkins and Schond L Greenway.
View institutional ownership trends
.

How do I buy shares of Avalo Therapeutics?

Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners